Correction: Trials 24, 56 (2023)  
https://doi.org/10.1186/s13063-022-07050-w

After publication of the article [1] the authors noticed several errors related to the inclusion and exclusion criteria. The clinical trial registration has been updated and the ethical committee has reviewed the changes.

**Incorrect**

Inclusion criteria
1) Age at study start 8.0–9.3 years;
2) BW for gestational age in lower tertile (−1.96 < Z-score < −0.44);
3) BMI for CA in upper tertile (+0.44 < Z-score < +1.96) [2];
4) Early progressive puberty [bilateral breast development (Tanner stage 2)] starting between 7.7 and 9.0 years, with a minimum of 4 months of progression) [3, 4];
5) White ethnicity;
6) Full-term pregnancy: 37 ≤ gestational age < 42 weeks;
7) Height at 1st visit: 3rd percentile ≤ height ≤ 97th percentile; and
8) Written informed consent of parents or legal representative.

**Correct**

Inclusion criteria
1) Age at study start 8.0–9.3 years;
2) BW for gestational age in lower tertile (−2.5 < Z-score < 0);
3) BMI for CA in upper tertile (0 < Z-score < +2.5) (2);
4) Early progressive puberty [bilateral breast development (Tanner stage 2)] starting between 7.7–9.3 years, with a minimum of 2 months of progression) (3,4);
5) White ethnicity;
6) Full-term or late preterm pregnancy: 34 ≤ gestational age < 42 weeks;
7) Height at 1st visit: 3rd percentile ≤ height ≤ 97th percentile (adjusted by pubertal stage);
8) Written informed consent of parents or legal representative.
Exclusion criteria

1) Excessive delay or advance of bone age (more than 2 years for chronological age);
2) Tanner stage of breast development greater than 2;
3) Twin pregnancy;
4) Obesity at 1st visit (BMI Z-score above + 1.96 for chronological age);
5) Evidence for a pathological cause of the rapid maturation (i.e., congenital adrenal hyperplasia due to 21-hydroxylase deficiency);
6) Known genetic abnormality or chronic conditions, including cardiovascular, neurological, immunological, metabolic, renal, endocrine, digestive, respiratory or oncological diseases;
7) Chronic use of medications, among others: anticoagulants, anti-inflammatory, oral hypoglycemic agents, androgens, estrogens, progestins, glucocorticoids, digoxin. Only the use of paracetamol before or during the course of the study will be accepted;
8) Acute infections or intake of antibiotics or anti-inflammatory medication in the last 14 days;
9) Previous history of hypersensitivity to any of the drugs used in the clinical trial, or to its excipients;
10) Any disease that, in the opinion of the investigator, compromises the inclusion of the subject in the clinical trial.

Reference